Answers are grounded in this paper and cite their sources.
Patients with Beta (β)-thalassemia require regular blood transfusions. The presence of red blood cell (RBC) alloantibodies can complicate transfusion treatment. This can lead to delays in obtaining compatible blood, and in some case temporarily rendering blood transfusion impossible. We present a case demonstrating the successful adjunctive management of a patient with transfusion-dependent β-thalassemia complicated by RBC alloimmunization using a novel therapeutic agent. A 32-year-old Thai female with homozygous β-thalassemia was admitted to the Hospital of Tropical Diseases, Bangkok, with symptoms of anemia. Cross-matching studies revealed the presence of alloantibodies at admission. Treatment with luspatercept, a novel erythroid maturation agent, resulted in an increase in hemoglobin levels and an extension of the transfusion interval. The patient received four doses of luspatercept while awaiting antigen-compatible RBC units. Although luspatercept had no direct effect on RBC alloimmunization or existing alloantibodies, its ability to reduce transfusion requirements may decrease the need for subsequent RBC transfusions, and thereby reduce further antigen exposure. This may be particularly beneficial in patients with complex alloantibody profiles. This case highlights the potential role of luspatercept as adjunctive supportive therapy to delay transfusions requirements in patients with transfusion-dependent β-thalassemia complicated by RBC alloimmunization.
No takes yet. Share an insight, caveat, or question.
Fairouz et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: